FOLFIRI + Bevacizumab (or ± cetuximab if RAS-WT left-sided)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-IRINOTECAN DRUG-LEUCOVORIN DRUG-5-FLUOROURACIL DRUG-BEVACIZUMAB |
|---|
| ID | REG-FOLFIRI-BEV |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
Standard 2L mCRC after FOLFOX progression. Adding bevacizumab (TML / ML18147 trial) improves PFS (5.7 vs 4.1 mo) + OS (11.2 vs 9.8 mo, HR 0.81) over FOLFIRI alone. Anti-EGFR (cetuximab or panitumumab) alternative add-on for RAS-WT left-sided patients in 2L if not used in 1L (or if patient progressed on bevacizumab). UGT1A1 testing recommended before high-dose irinotecan use. Cholinergic syndrome vs delayed diarrhea — distinct pathophysiology + management.
Used By
Indication
IND-CRC-METASTATIC-2L-FOLFIRI-BEV- IND-CRC-METASTATIC-2L-FOLFIRI-BEV